Mutated in Colorectal Cancers Antibody / MCC
MUTATED IN COLORECTAL CANCERS (MCC) is a tumor suppressor gene. It is mapped to 5q22.2. This gene suppresses cell proliferation and the Wnt/b-catenin pathway in colorectal cancer cells. MCC also Inhibits DNA binding of b-catenin/TCF/LEF transcription factors, and it is Involved in cell migration independently of RAC1, CDC42 and p21-activated kinase (PAK) activation. What's more, MCC can interact with SCRIB (via phosphorylated PDZ-binding motif), EZR, SNX27, SLC9A3R1 and SLC9A3R2.
Product Specifications
Specifications
Western blot: 1-2 µg/mL, Flow cytometry: 1-3ug/million cells, Direct ELISA: 0.1-0.5 µg/mL
UniProt
P23508
Host
Rabbit
Reactivity
Human, Mouse, Rat
Immunogen
Recombinant human protein (amino acids M1-E234) was used as the immunogen for the Mutated in Colorectal Cancers antibody.
Clonality
Polyclonal
Isotype
IgG
Applications
WB, FACS, Direct ELISA
Purity
Antigen affinity purified
Format
Antigen affinity purified
Buffer
Lyophilized from 1X PBS with 2% Trehalose
Reconstitution
Limitations
This Mutated in Colorectal Cancers antibody is available for research use only.
Storage Conditions
Product Datasheet
https://www.nsjbio.com/tds-pdf/mutated-in-colorectal-cancers-antibody-mcc-rq6655
Formulation
0.5 mg/mL if reconstituted with 0.2ml sterile DI water
Applications Notes
Optimal dilution of the Mutated in Colorectal Cancers antibody should be determined by the researcher.
CAS Number
9007-83-4
Image Legend
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
